GlassScriptPhysician profile
Renato Gega
NPI 1326000977
$958.32
in general payments reported to CMS, 2019-2025
14 companies · $235 in 2025
The $235 reported for 2025 was more than what 78% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.12 · 2020: $78.74 · 2021: $240 · 2022: $30.46 · 2023: $189 · 2024: $140 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $564.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $469.08 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Welch Allyn | $119.76 | 2021 | |
| Endo USA, INC. | $81.45 | 2025 | Supprelin |
| Ascendis Pharma Endocrinology INC | $61.62 | 2023-2025 | Skytrofa |
| Hologic Sales and Service, LLC | $40.58 | 2025 | Aptima |
| Merck Sharp & Dohme LLC | $28.47 | 2025 | M-M-R II, Rotateq, Gardasil 9 |
| Tolmar, INC. | $25.02 | 2025 | Fensolvi |
| Azurity Pharmaceuticals, INC. | $24.18 | 2024 | Triptodur |
| Biomarin Pharmaceutical INC. | $19.73 | 2024 | Voxzogo 1.2mg |
| Rhythm Pharmaceuticals, INC. | $18.06 | 2023 | Imcivree |
| Dexcom, INC. | $17.96 | 2024 | Dexcom G6 Transmitter |
| Phadia US INC. | $17.96 | 2024 | Immunocap |
| Cumberland Pharmaceuticals, INC. | $17.61 | 2023 | Kristalose |
| Pfizer INC. | $16.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renato Gega listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.